During the last session, Selecta Biosciences Inc. (NASDAQ:SELB)’s traded shares were 2.36 million, with the beta value of the company hitting 1.35. At the end of the trading day, the stock’s price was $0.69, reflecting an intraday gain of 2.88% or $0.02. The 52-week high for the SELB share is $5.28, that puts it down -665.22 from that peak though still a striking 5.8% gain since the share price plummeted to a 52-week low of $0.65. The company’s market capitalization is $99.21M, and the average trade volume was 1.18 million shares over the past three months.
Selecta Biosciences Inc. (SELB) received a consensus recommendation of a Buy from analysts. That translates to a mean rating of 1.60. SELB has a Sell rating from 0 analyst(s) out of 6 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 6 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -$0.07.
Selecta Biosciences Inc. (NASDAQ:SELB) trade information
Selecta Biosciences Inc. (SELB) registered a 2.88% upside in the last session and has traded in the red over the past 5 sessions. The stock spiked 2.88% in intraday trading to $0.69 this Thursday, 05/12/22, hitting a weekly high. The stock’s 5-day price performance is -14.36%, and it has moved by -34.56% in 30 days. Based on these gigs, the overall price performance for the year is -76.32%.
The consensus price target of analysts on Wall Street is $8.20, which implies an increase of 91.59% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $6.00 and $13.00 respectively. As a result, SELB is trading at a discount of -1784.06% off the target high and -769.57% off the low.
Selecta Biosciences Inc. (SELB) estimates and forecasts
Statistics show that Selecta Biosciences Inc. has underperformed its competitors in share price, compared to the industry in which it operates. Selecta Biosciences Inc. (SELB) shares have gone down -81.35% during the last six months, with a year-to-date growth rate less than the industry average at -40.00% against -0.10. Yet analysts are ramping up their growth forecast for the fiscal year 2022. Revenue is predicted to grow 50.00% this quarter and then jump 50.00% in the quarter after that. In the rating firms’ projections, revenue will increase 329.70% compared to the previous financial year.
Revenue for the current quarter is expected to be $17.58 million as predicted by 7 analyst(s). Meanwhile, a consensus of 6 analyst(s) estimates revenue growth to $13.22 million by the end of Mar 2022. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled $11.95 million and $11.05 million respectively. In this case, analysts expect current quarter sales to grow by 47.10% and then jump by 19.60% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 43.50%. While earnings are projected to return 67.00% in 2022.
Selecta Biosciences Inc. is due to release its next quarterly earnings between March 09 and March 14. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Selecta Biosciences Inc. (NASDAQ:SELB)’s Major holders
Selecta Biosciences Inc. insiders own 31.49% of total outstanding shares while institutional holders control 47.09%, with the float percentage being 68.73%. Blackrock Inc. is the largest shareholder of the company, while 150 institutions own stock in it. As of Sep 29, 2021, the company held over 6.97 million shares (or 5.97% of all shares), a total value of $28.98 million in shares.
The next largest institutional holding, with 5.06 million shares, is of Vanguard Group, Inc. (The)’s that is approximately 4.34% of outstanding shares. At the market price on Sep 29, 2021, these shares were valued at $21.07 million.
Also, the Mutual Funds coming in first place with the largest holdings of Selecta Biosciences Inc. (SELB) shares are SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and Vanguard Total Stock Market Index Fund. Data provided on Sep 29, 2021 indicates that SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF owns about 2.73 million shares. This amounts to just over 2.34 percent of the company’s overall shares, with a $11.38 million market value. The same data shows that the other fund manager holds slightly less at 2.49 million, or about 2.13% of the stock, which is worth about $10.36 million.